Skip to main content

Vancomycin May Be Losing Strength Against Common Deadly Infection

Medically reviewed by Carmen Pope, BPharm. Last updated on April 26, 2024.

By Ernie Mundell HealthDay Reporter

FRIDAY, April 26, 2024 -- Clostridioides difficile (C. difficile) is a leading cause of illness and death, especially for frail and hospitalized Americans.

Now, a new study suggests that the leading antibiotic used to fight it, vancomycin, may be losing potency against this killer.

“It's an alarming development in the field of C. diff, as there are only two recommended antibiotics,” noted study co-author Dr. Kevin Garey, a professor of pharmacy practice and translational research at the University of Houston College of Pharmacy.

The second-line drug is fidaxomicin (Dificid).

“If antimicrobial resistance increases in both antibiotics, it will complicate the management of C. diff infection leading us back to a pre-antibiotic era," Garey said in a university news release.

According to the U.S. Centers for Disease Control and Prevention, in 2017 C. difficile killed about 12,800 people and sickened 223,900 more. The bacterium causes a bowel infection known as gastroenteritis, which can lead to diarrhea, abdominal pain and toxic megacolon (severe inflammation of the colon), sepsis and death.

It's especially deadly for the frail elderly or people with weakened immune systems.

Vancomycin has long been the go-to antibiotic of choice against C. difficile, with its use jumping 54% in the past six years, according to Garey and colleagues.

But its power to fight the bacterium may be waning: In the early 2000s, vancomycin cleared up nearly 100% of C. difficile cases but more recently that cure rate has dropped to 70%, the Houston team said.

They looked at data from a multi-center study that tracked levels of resistance to vancomycin in 300 samples of C. difficile bacteria sourced from adults who'd been treated between 2016 and 2021.

Overall, 34% of C. difficile samples tested "exhibited reduced vancomycin susceptibility," the team reported recently in the journal Clinical Infectious Diseases.

This weakening of vancomycin “was associated with lower 30-day sustained clinical response and lower 14-day initial cure rates in the studied patient cohort,” noted senior study author Anne Gonzales-Luna. She's a research assistant professor of pharmacy practice and translational research at the university.

Sources

  • University of Houston College of Pharmacy, news release, April 25, 2024
  • Clinical Infectious Diseases

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

Simple Antibiotic Switch for Pneumonia Patients Could Prevent Hospital Infection

THURSDAY, Nov. 2, 2023 -- A new study on Clostridioides difficile infections finds that choosing an alternative antibiotic for high-risk patients with pneumonia can reduce...

Patient-to-Patient Transmission Not to Blame for Most C. Difficile Infections in Hospitals

WEDNESDAY, Sept. 20, 2023 -- A deadly infection associated with hospitalization may not be the fault of the hospital, but may instead stem from the patients themselves, a new...

How NSAIDs Can Make a C. Difficile Infection Worse

FRIDAY, July 21, 2023 -- Aspirin, naproxen and other common pain medications known as NSAIDs worsen gastrointestinal infections caused by a bacterium known as Clostridioides...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.